4. Central Nervous System
| First line drugs | Second line drugs | Specialist drugs | Secondary care drugs |
| Recommended in both primary and secondary care | Alternatives (often in specific conditions) in both primary and secondary care; | Where a specialist input is needed (see introduction for definition) | Prescribing principally within secondary care only |
Controlled drugs are highlighted with the symbol CD. Full details of the regulations appear in the BNF.
Part 1 excludes Cornwall Partnership Trust and Devon Partnership Trust Patients
- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.2.1 Antipsychotic drugs
- 4.2.2 Antipsychotic depot injections
- 4.2.3 Antimanic drugs
- 4.3.1 Tricyclic (TCA) and related antidepressant drug
- 4.3.2 Monoamine–oxidase inhibitors
- 4.3.3 Selective serotonin re–uptake inhibitors (SSRIs)
- 4.3.4 Other antidepressant drugs
- 4.4 Central nervous system stimulants
- 4.5.1 Drugs used in the treatment of obesity
- 4.5.2 Centrally acting appetite suppressants
- 4.6 Drugs used in nausea and vertigo
- 4.7.1 Non opioid analgesics and compound analgesic preparations
- 4.7.2 Opioid analgesics
- 4.7.3 Neuropathic pain
- 4.7.4 Antimigraine drugs
- 4.8.1 Control of epilepsy
- 4.8.2 Status epilepticus
- 4.8.3 Febrile convulsions
- 4.9.1 Dopaminergic drugs used in Parkinson’s Disease
- 4.9.2 Antimuscarinic drugs used in parkinsonism
- 4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders
- 4.10.1 Alcohol dependence
- 4.10.2 Nicotine dependence
- 4.10.3 Opioid dependence
- 4.11 Drugs for dementia
Appendices
- Appendix 01 Prioritisation guidelines for mental health
- Appendix 02 Children and Adolescent Mental Health
- Appendix 03 Hypnotics (benzodiazepines and zhypnitics) reducing prescribing in general practice
- Appendix 04 Management of anxiety in adults
- Appendix 05 Prescribing Psychotropics in Problem Areas
- Appendix 06 Prescribing Antipsychotics for Elderly Patients
- Appendix 07 Oral Atypical antipsychotic prescribing for schizophrenia
- Appendix 08 Guidance for the measurement of Prolactin in Patients Receiving Antipsychotics
- Appendix 09 Schizophrenia management of physical care
- Appendix 10 Management of acute confusion (delirium) in older people
- Appendix 11 Antidepressants prescribing advice
- Appendix 12 Derriford Hospital Pain ladder
- Appendix 13 Treatment of Non Malignant Pain and algorithm
- Appendix 14 Guidelines for prescribing Effentora
- Appendix 15 Management of neuropathic pain
- Appendix 16 Management of pain in patients with substance use disorders
- Appendix 17 Prescribing guidelines for buccal midazolam
- Appendix 18 Smoking Cessation
Last updated by: Carol Webb on 11-01-2013 14:23
Please click on the links below for more information
-
BNF
-
NICE
-
Summary of product characteristics
